NASDAQ$MGNX
MacroGenics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
MacroGenics reported first quarter 2023 financial results and provided a corporate progress update.
MacroGenics reported a net loss of $38.0 million for the quarter ended March 31, 2023, compared to a net loss of $66.4 million for the quarter ended March 31, 2022. Total revenue was $24.5 million, compared to $11.1 million for the quarter ended March 31, 2022. The company's cash, cash equivalents and marketable securities were $241.7 million as of March 31, 2023, and anticipates its cash runway through 2025.
- ZYNYZ™ is the third product approved in the U.S. that originated from MacroGenics' pipeline.
- Multiple Phase 2 programs are advancing in metastatic castration-resistant prostate cancer (mCRPC).
- The company achieved $270 million in non-dilutive funding over the past nine months.
- Cash runway extends through 2025.
Headline financials
Revenue & EPS history
MacroGenics · Revenue · Quarterly
$24.5M
Revenue by segment
MacroGenics · $3.9M total across 2 segments · Q1 2023
- Contract Manufacturing$3.62M—92.7%
- Government Agreements$283K-33.9%7.3%
Forward guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $241.7 million as of March 31, 2023, plus projected and anticipated future payments from partners and product revenues should extend its cash runway through 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+5.6%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+3.4%
Avg return
30 days after
44%
23 / 52 earnings
Positive
+251.7%
Q1 2020
Best reaction
-77.4%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | +24.0% | +12.9% | |
| Q4 2025 | +45.3% | +27.1% | +45.8% | |
| Q3 2025 | +8.3% | +4.8% | -4.8% | |
| Q1 2025 | +0.0% | +0.0% | -5.1% | |
| Q4 2024 | -4.8% | -25.7% | -40.0% | |
| Q3 2024 | +13.2% | +17.6% | -8.4% | |
| Q2 2024 | -5.6% | -1.7% | -5.6% | |
| Q1 2024 | -77.4% | -69.6% | -69.1% | |
| Q4 2023 | -18.8% | -18.0% | -15.0% | |
| Q3 2023 | +20.0% | +20.5% | +62.7% | |
| Q2 2023 | +26.6% | +13.7% | +4.7% | |
| Q1 2023 | -0.4% | -9.1% | -28.2% | |
| Q4 2022 | +8.4% | +3.7% | +0.6% | |
| Q3 2022 | +22.1% | +30.1% | +42.3% | |
| Q2 2022 | +16.2% | +18.9% | -3.6% | |
| Q1 2022 | -15.2% | -38.2% | -56.5% | |
| Q4 2021 | -3.6% | -8.1% | -12.7% | |
| Q3 2021 | +4.1% | +5.1% | -16.7% | |
| Q2 2021 | -5.5% | -5.7% | -10.3% | |
| Q1 2021 | -8.3% | -9.8% | -8.8% | |
| Q4 2020 | +18.7% | +16.1% | +57.6% | |
| Q3 2020 | +4.9% | +0.9% | +19.9% | |
| Q2 2020 | -1.5% | +3.1% | +5.9% | |
| Q1 2020 | +251.7% | +184.5% | +186.4% | |
| Q4 2019 | +8.5% | -20.8% | -45.5% | |
| Q3 2019 | -0.9% | -6.5% | +13.9% | |
| Q2 2019 | -0.3% | -9.1% | -2.5% | |
| Q1 2019 | +3.4% | +9.7% | +9.4% | |
| Q4 2018 | -2.8% | -5.8% | -19.4% | |
| Q3 2018 | +8.7% | -1.0% | -2.3% | |
| Q2 2018 | +6.3% | +9.5% | +11.1% | |
| Q1 2018 | -9.2% | -7.8% | +2.8% | |
| Q4 2017 | +2.1% | +17.7% | +2.4% | |
| Q3 2017 | -1.6% | -0.3% | +8.9% | |
| Q2 2017 | +6.6% | +8.0% | +17.8% | |
| Q1 2017 | -1.7% | -12.2% | -9.9% | |
| Q4 2016 | -5.1% | -2.7% | -15.8% | |
| Q3 2016 | -16.3% | -6.0% | +10.4% | |
| Q2 2016 | +6.8% | +1.1% | -2.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +5.1% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -12.1% | — | — | |
| Q1 2015 | +9.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | +17.5% | — | — | |
| Q2 2014 | -4.8% | — | — | |
| Q2 2013 | -4.8% | — | — | |
| Q1 2014 | -5.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2013 | -7.6% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro